Comparison · NCT02138253-9eb93258
IDN-6556 vs Placebo: Number of Participants With At Least a One Stage Reduction From Baseline in Ishak Fibrosis Score
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. IDN-6556 vs Placebo: Number of Participants With At Least a One Stage Reduction From Baseline in Ishak Fibrosis Score. Trial comparisons, record NCT02138253-9eb93258. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02138253-9eb93258
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.61 | 0.457 | 0.743 | wilson | |
| Risk in group 2 | 0.609 | 0.408 | 0.778 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00106 | -0.227 | 0.242 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1 | 0.665 | 1.51 | log | |
| Odds ratio, group 1 over group 2 | 1 | 0.353 | 2.86 | log | |
| Number needed to treat, for one more participant with the outcome on IDN-6556 than on Placebo | 943 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | IDN-6556 | IDN-6556 25 mg BID~IDN-6556 | 25 | 41 | OG000 |
| Group 2 | Placebo | Placebo BID~Placebo: Placebo control | 14 | 23 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants With At Least a One Stage Reduction From Baseline in Ishak Fibrosis Score
- Description
At least a one stage reduction from baseline in Ishak Fibrosis Stage. Score F0 No fibrosis F1 Fibrous expansion of some portal areas, with or without short fibrous septa F2 Fibrous expansion of most portal areas, with or without short fibrous septa F3 Fibrous expansion of most portal areas, with occasional portal to portal bridging F4 Fibrous expansion of portal areas, with marked bridging (portal to portal as well as portal to central) F5 Marked bridging (portal to portal and/or portal to central) with occasional nodules (incomplete cirrhosis) F6 Cirrhosis probable or definite~Since the primary analysis used multiple imputation methodology, the numerator and denominator varied across 20 imputations.
- Time frame
- 24 months
- Population
- The Full Analysis Set (FAS) consisted of all randomized subjects who received at least 1 dose of study drug.
Source ClinicalTrials.gov
Trial
- Title
- A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV
- NCT number
- NCT02138253
- Phases
- PHASE2
- Conditions
- Liver Fibrosis, Hepatic Fibrosis, Liver Cirrhosis, Hepatic Cirrhosis
- Interventions
- IDN-6556, Placebo
- Lead sponsor
- Conatus Pharmaceuticals Inc.
- Results first posted
- 2019-12-11
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02138253?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02138253-9eb93258